Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Toxicol Sci ; 125(1): 310-7, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21998131

RESUMEN

Several million people are exposed to dioxin and dioxin-like compounds, primarily through food consumption. Skin lesions historically called "chloracne" are the most specific sign of abnormal dioxin exposure and classically used as a key marker in humans. We followed for 5 years a man who had been exposed to the most toxic dioxin, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), at a single oral dose of 5 million-fold more than the accepted daily exposure in the general population. We adopted a molecular medicine approach, aimed at identifying appropriate therapy. Skin lesions, which progressively covered up to 40% of the body surface, were found to be hamartomas, which developed parallel to a complete and sustained involution of sebaceous glands, with concurrent transcriptomic alterations pointing to the inhibition of lipid metabolism and the involvement of bone morphogenetic proteins signaling. Hamartomas created a new compartment that concentrated TCDD up to 10-fold compared with serum and strongly expressed the TCDD-metabolizing enzyme cytochrome P450 1A1, thus representing a potentially significant source of enzymatic activity, which may add to the xenobiotic metabolism potential of the classical organs such as the liver. This historical case provides a unique set of data on the human tissue response to dioxin for the identification of new markers of exposure in human populations. The herein discovered adaptive cutaneous response to TCDD also points to the potential role of the skin in the metabolism of food xenobiotics.


Asunto(s)
Hamartoma/inducido químicamente , Dibenzodioxinas Policloradas/envenenamiento , Enfermedades de la Piel/inducido químicamente , Piel/efectos de los fármacos , Biopsia , Expresión Génica/efectos de los fármacos , Perfilación de la Expresión Génica , Hamartoma/genética , Hamartoma/patología , Hamartoma/terapia , Humanos , Masculino , Persona de Mediana Edad , Imagen Multimodal , Dibenzodioxinas Policloradas/farmacocinética , Tomografía de Emisión de Positrones , Piel/metabolismo , Piel/patología , Enfermedades de la Piel/genética , Enfermedades de la Piel/patología , Enfermedades de la Piel/terapia , Tomografía Computarizada por Rayos X , Resultado del Tratamiento
2.
Genes Chromosomes Cancer ; 51(2): 174-85, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22045684

RESUMEN

Epigenetic modifications such as methylation of CpG islands in tumor-suppressor gene promoter regions have been associated with tumor development in many human cancers. Using methylation specific multiplex ligation-dependent probe amplification method, we analyzed the methylation status of 35 different genes in 16 neuroblastoma (NB) cell lines and 50 NB tumor samples (NBs), and investigated whether specific hypermethylation was associated with biological and/or clinical parameters. Among the genes found hypermethylated, the effect of GSTP1 hypermethylation on mRNA and protein expression was also explored. The median number of hypermethylated genes was higher in cell lines compared to NBs (5.5 vs. 2). For eight genes, aberrant methylation of CpG-islands in NB was not (ESR1, PAX5, WT1, CADM1, MSH6, and CDKN2B) or very rarely (CDH13 and GSTP1) reported in literature. GSTP1 was found hypermethylated in 44% of the NB cell lines and in 33% of the stage 4-11qLOH -non MYCN-amplified high risk NBs. Hypermethylation was correlated with reduced mRNA and protein expression. In the whole NBs cohort, GSTP1 hypermethylation was less frequently detected (8%), but found to be associated with lower event-free (EFS) and overall survival. Hypermethylation of GSTP1 showed also association with lower EFS in high risk subgroups as stage 4 and older patients (≥547 days). Our results suggest that, as in several adult cancers, aberrant methylation of GSTP1 may contribute to the carcinogenetic process in NB and could be potentially used as a new marker leading to define an ultra-high risk subgroup.


Asunto(s)
Biomarcadores de Tumor/genética , Metilación de ADN , Regulación hacia Abajo , Gutatión-S-Transferasa pi/genética , Neoplasias del Sistema Nervioso/genética , Neuroblastoma/genética , Adolescente , Biomarcadores de Tumor/metabolismo , Estudios de Casos y Controles , Línea Celular Tumoral , Niño , Preescolar , Expresión Génica , Regulación Neoplásica de la Expresión Génica , Estudios de Asociación Genética , Gutatión-S-Transferasa pi/metabolismo , Humanos , Lactante , Recién Nacido , Estimación de Kaplan-Meier , Pérdida de Heterocigocidad , Neoplasias del Sistema Nervioso/metabolismo , Neoplasias del Sistema Nervioso/mortalidad , Neoplasias del Sistema Nervioso/patología , Neuroblastoma/metabolismo , Neuroblastoma/mortalidad , Neuroblastoma/patología , Pronóstico , Regiones Promotoras Genéticas
3.
Breast Cancer Res Treat ; 127(3): 671-9, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20652400

RESUMEN

The c.156_157insAlu BRCA2 mutation has so far only been reported in hereditary breast/ovarian cancer (HBOC) families of Portuguese origin. Since this mutation is not detectable using the commonly used screening methodologies and must be specifically sought, we screened for this rearrangement in a total of 5,443 suspected HBOC families from several countries. Whereas the c.156_157insAlu BRCA2 mutation was detected in 11 of 149 suspected HBOC families from Portugal, representing 37.9% of all deleterious mutations, in other countries it was detected only in one proband living in France and in four individuals requesting predictive testing living in France and in the USA, all being Portuguese immigrants. After performing an extensive haplotype study in carrier families, we estimate that this founder mutation occurred 558 ± 215 years ago. We further demonstrate significant quantitative differences regarding the production of the BRCA2 full length RNA and the transcript lacking exon 3 in c.156_157insAlu BRCA2 mutation carriers and in controls. The cumulative incidence of breast cancer in carriers did not differ from that of other BRCA2 and BRCA1 pathogenic mutations. We recommend that all suspected HBOC families from Portugal or with Portuguese ancestry are specifically tested for this rearrangement.


Asunto(s)
Neoplasias de la Mama/epidemiología , Neoplasias de la Mama/genética , Genes BRCA2 , Mutación , Neoplasias Ováricas/epidemiología , Neoplasias Ováricas/genética , Secuencia de Aminoácidos , Femenino , Efecto Fundador , Predisposición Genética a la Enfermedad , Pruebas Genéticas , Genética de Población , Humanos , Repeticiones de Microsatélite , Reacción en Cadena de la Polimerasa , Polimorfismo de Nucleótido Simple , Portugal/epidemiología , ARN Mensajero/análisis , Sistemas de Lectura/genética , Eliminación de Secuencia
6.
Endocrinology ; 144(11): 4905-15, 2003 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-12960096

RESUMEN

In adrenal glomerulosa cells, the stimulation of aldosterone biosynthesis by angiotensin II (Ang II) occurs via activation of the Ca2+ messenger system, increased expression of the steroidogenic acute regulatory protein, and enhanced transfer of cholesterol to the inner mitochondrial membrane. We examined here whether Ang II affects the activity of cholesterol ester hydrolase (CEH), also named hormone-sensitive lipase, the enzyme recruiting cholesterol from intracellular pools, in bovine adrenal glomerulosa cells. In bovine adrenal tissue, CEH activity was detected with characteristics similar to those reported in other tissues (Michaelis constant = 46.3 +/- 6.7 microM, n = 3; maximal velocity = 1 nmol/mg.min). This activity was significantly enhanced in isolated bovine glomerulosa cells challenged for 2 h with 10 nM Ang II (to 149 +/- 11% of controls, n = 3). Similarly, 25 microM forskolin raised CEH activity to 151 +/- 5% of controls (n = 3). This increase in activity of CEH was not due to an increase in the amount of enzyme protein but was associated with an increased phosphorylation of the enzyme to 337 +/- 33% of controls (n = 9, P < 0.0001). Potassium ion (K+) and forskolin also stimulated [32P]orthophosphate incorporation, although to a lesser extent (to 157 +/- 18% and 186 +/- 25% of controls, respectively). On SDS-PAGE, the majority of this radioactivity was associated with a species of 172 kDa, corresponding to a CEH dimer. Both Ang II-induced CEH phosphorylation and pregnenolone production were significantly reduced (to 47 +/- 6% and 50 +/- 8% of controls with Ang II alone, respectively) in the presence of PD098059, an inhibitor of p42/p44 MAPK. Indeed, Ang II challenge led to a rapid 32P incorporation into p42/p44 MAPK. These results demonstrate that, in addition to its known effects on intramitochondrial cholesterol transfer, Ang II also promotes aldosterone biosynthesis by rapidly increasing cholesterol supply to the outer mitochondrial membrane.


Asunto(s)
Angiotensina II/farmacología , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Esterol Esterasa/metabolismo , Zona Glomerular/enzimología , Animales , Proteínas Quinasas Dependientes de Calcio-Calmodulina/metabolismo , Bovinos , Células Cultivadas , Colforsina/farmacología , Activación Enzimática/efectos de los fármacos , Proteína Quinasa 3 Activada por Mitógenos , Fosforilación/efectos de los fármacos , Potasio/farmacología , Proteína Quinasa C/metabolismo , Zona Glomerular/citología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...